Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Development by Year
Development — Clinical drug supply & lab supplies (standalone through FY2018, $M) ($M)
Vertex Pharmaceuticals Development: $84.9M in FY2018, up 86.2% from a year earlier. No newer figure appears in the documents we track.
Where the FY2018 figure comes from
“|| Laboratory supplies and other direct expenses | 84,900 | 45,594 | 42,861 | 39,306 | 86 | % | 2,733 | 6 | %”
Source: Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗
Reported in Form 10-Q / 10-K MD&A (Development Expenses Disaggregation Table).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Development — Clinical drug supply & lab supplies (standalone through FY2018, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2018 | Dec 31, 2018 | 84.9 | +86.2% | Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 45.6 | +6.3% | Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 42.9 | +40.2% | Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 30.6 | -11.8% | Form 10-K (a201710k-main.htm, filed 2018-02-15) ↗ |
| FY2014 | Dec 31, 2014 | 34.7 | -9.9% | Form 10-K (a201610k-main.htm, filed 2017-02-23) ↗ |
| FY2013 | Dec 31, 2013 | 38.5 | – | Form 10-K (a201510k-main.htm, filed 2016-02-16) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Development ($M), annual FY2013–FY2018 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rd-dev-lab-supplies
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.